Correlation Between Lixte Biotechnology and NLS Pharmaceutics

Can any of the company-specific risk be diversified away by investing in both Lixte Biotechnology and NLS Pharmaceutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lixte Biotechnology and NLS Pharmaceutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lixte Biotechnology Holdings and NLS Pharmaceutics AG, you can compare the effects of market volatilities on Lixte Biotechnology and NLS Pharmaceutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lixte Biotechnology with a short position of NLS Pharmaceutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lixte Biotechnology and NLS Pharmaceutics.

Diversification Opportunities for Lixte Biotechnology and NLS Pharmaceutics

0.51

Correlation Coefficient

Lixte Biotechnology  NLS Pharmaceutics

Very weak diversification

The 3 months correlation between Lixte and NLS is 0.51. Overlapping area represents the amount of risk that can be diversified away by holding Lixte Biotechnology Holdings and NLS Pharmaceutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NLS Pharmaceutics and Lixte Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lixte Biotechnology Holdings are associated (or correlated) with NLS Pharmaceutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NLS Pharmaceutics has no effect on the direction of Lixte Biotechnology i.e., Lixte Biotechnology and NLS Pharmaceutics go up and down completely randomly.

Pair Corralation between Lixte Biotechnology and NLS Pharmaceutics

Given the investment horizon of 90 days Lixte Biotechnology Holdings is expected to under-perform the NLS Pharmaceutics. But the stock apears to be less risky and, when comparing its historical volatility, Lixte Biotechnology Holdings is 1.58 times less risky than NLS Pharmaceutics. The stock trades about -0.09 of its potential returns per unit of risk. The NLS Pharmaceutics AG is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  182.00  in NLS Pharmaceutics AG on December 27, 2024 and sell it today you would lose (28.00) from holding NLS Pharmaceutics AG or give up 15.38% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Lixte Biotechnology Holdings  vs.  NLS Pharmaceutics AG

Lixte Biotechnology

Risk-Adjusted Performance

Very Weak

Over the last 90 days Lixte Biotechnology Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

NLS Pharmaceutics

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in NLS Pharmaceutics AG are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, NLS Pharmaceutics may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Lixte Biotechnology and NLS Pharmaceutics

The main advantage of trading using opposite Lixte Biotechnology and NLS Pharmaceutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lixte Biotechnology position performs unexpectedly, NLS Pharmaceutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NLS Pharmaceutics will offset losses from the drop in NLS Pharmaceutics' long position.

The idea behind Lixte Biotechnology Holdings and NLS Pharmaceutics AG pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.